-
Mashup Score: 0Costly Gadgets: Barriers to Market Entry and Price Competition for Generic Drug-Device Combinations in the United States - 1 year(s) ago
Prescription drug prices continue to rise unabated in the United States, largely due to a system that allows brand-name drug makers to charge whatever the marke
Source: papers.ssrn.comCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 6Costly Gadgets: Barriers to Market Entry and Price Competition for Generic Drug-Device Combinations in the United States - 2 year(s) ago
By Michael S. Sinha, Published on 02/22/22
Source: Scholarship RepositoryCategories: Healthcare Professionals, Latest HeadlinesTweet
-
Mashup Score: 1Costly Gadgets: Barriers to Market Entry and Price Competition for Generic Drug-Device Combinations in the United States - 2 year(s) ago
By Michael S. Sinha, Published on 02/22/22
Source: Scholarship RepositoryCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 2Costly Gadgets: Barriers to Market Entry and Price Competition for Generic Drug-Device Combinations in the United States - 2 year(s) ago
Prescription drug prices continue to rise unabated in the United States, largely due to a system that allows brand-name drug makers to charge whatever the marke
Source: papers.ssrn.comCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 1Costly Gadgets: Barriers to Market Entry and Price Competition for Generic Drug-Device Combinations in the United States - 2 year(s) ago
Prescription drug prices continue to rise unabated in the United States, largely due to a system that allows brand-name drug makers to charge whatever the marke
Source: papers.ssrn.comCategories: Cardiologists, Latest HeadlinesTweet
#CostlyGadgets: "In addition to new versions of Humira, AbbVie has also introduced new biologic products risankizumab [Skyrizi] and upadacitinib [Rinvoq] to capture additional market share that may be lost to adalimumab biosimilars." https://t.co/b56i7e2IU8 Today: https://t.co/kV4JTZzwHK